Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1

J Biol Chem. 2004 Mar 26;279(13):12647-58. doi: 10.1074/jbc.M312972200. Epub 2004 Jan 13.

Abstract

Microsomal prostaglandin E synthase-1 (mPGES-1) catalyzes the conversion of cyclooxygenase-derived prostaglandin (PG) H(2) to PGE(2). Increased amounts of mPGES-1 were detected in inflamed intestinal mucosa from patients with inflammatory bowel disease (IBD). Treatment with tumor necrosis factor (TNF)-alpha stimulated mPGES-1 transcription in human colonocytes, resulting in increased amounts of mPGES-1 mRNA and protein. The inductive effect of TNF-alpha localized to the GC box region of the mPGES-1 promoter. Binding of Egr-1 to the GC box region of the mPGES-1 promoter was enhanced by treatment with TNF-alpha. Notably, increased Egr-1 expression and binding activity were also detected in inflamed mucosa from IBD patients. Treatment with TNF-alpha induced the activities of phosphatidylcholine-phospholipase C (PC-PLC) and protein kinase (PK) C and enhanced NO production. A pharmacological approach was used to implicate PC-PLC --> PKC --> NO signaling as being important for the induction of mPGES-1 by TNF-alpha. TNF-alpha also enhanced guanylate cyclase activity and inhibitors of guanylate cyclase activity blocked the induction of mPGES-1 by TNF-alpha. YC-1, an activator of guanylate cyclase, induced mPGES-1. Overexpressing a dominant negative form of PKG blocked TNF-alpha-mediated stimulation of the mPGES-1 promoter. Taken together, these results suggest that overexpression of mPGES-1 in IBD is the result of Egr-1-mediated activation of transcription. Moreover, TNF-alpha induced mPGES-1 by stimulating PC-PLC --> PKC --> NO --> cGMP --> PKG signal transduction pathway.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Blotting, Northern
  • Blotting, Western
  • Cell Line, Tumor
  • Cells, Cultured
  • Colon / cytology
  • DNA-Binding Proteins / metabolism*
  • Dose-Response Relationship, Drug
  • Early Growth Response Protein 1
  • Enzyme Activators / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Guanylate Cyclase / metabolism
  • Humans
  • Immediate-Early Proteins*
  • Immunoblotting
  • Immunohistochemistry
  • Indazoles / pharmacology
  • Inflammation
  • Inflammatory Bowel Diseases / enzymology*
  • Intestinal Mucosa / metabolism
  • Intestinal Mucosa / pathology
  • Intramolecular Oxidoreductases / biosynthesis*
  • Luciferases / metabolism
  • Microsomes / enzymology*
  • Models, Biological
  • Nitric Oxide / metabolism
  • Oligonucleotides, Antisense / pharmacology
  • Plasmids / metabolism
  • Promoter Regions, Genetic
  • Prostaglandin-E Synthases
  • Protein Kinase C / metabolism
  • RNA Interference
  • Signal Transduction
  • Transcription Factors / metabolism*
  • Transcription, Genetic
  • Transfection
  • Tumor Necrosis Factor-alpha / metabolism
  • Type C Phospholipases / metabolism

Substances

  • DNA-Binding Proteins
  • EGR1 protein, human
  • Early Growth Response Protein 1
  • Enzyme Activators
  • Enzyme Inhibitors
  • Immediate-Early Proteins
  • Indazoles
  • Oligonucleotides, Antisense
  • Transcription Factors
  • Tumor Necrosis Factor-alpha
  • 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
  • Nitric Oxide
  • Luciferases
  • Protein Kinase C
  • Type C Phospholipases
  • phosphatidylcholine-specific phospholipase C
  • Guanylate Cyclase
  • Intramolecular Oxidoreductases
  • PTGES protein, human
  • Prostaglandin-E Synthases